Author: Wang, Xiaona; Li, Fengsai; Han, Meijing; Jia, Shuo; Wang, Li; Qiao, Xinyuan; Jiang, Yanping; Cui, Wen; Tang, Lijie; Li, Yijing; Xu, Yi-Gang
Title: Cloning, Prokaryotic Soluble Expression, and Analysis of Antiviral Activity of Two Novel Feline IFN-? Proteins Document date: 2020_3_19
ID: 1me7ugkg_43
Snippet: In this study, two new subtypes of feline IFN-ω (ωa and ωb) were identified and characterized. They shared a maximum nucleotide sequence homology of 91.88% and 90.20% and a maximum amino acid homology of 91.6% and 89.4% with the 13 previously known subtypes of feIFN-ω, respectively. We analyzed the characteristics of feIFN-ωa and feIFN-ωb in detail using bioinformatics followed by soluble expression and optimization of induction conditions .....
Document: In this study, two new subtypes of feline IFN-ω (ωa and ωb) were identified and characterized. They shared a maximum nucleotide sequence homology of 91.88% and 90.20% and a maximum amino acid homology of 91.6% and 89.4% with the 13 previously known subtypes of feIFN-ω, respectively. We analyzed the characteristics of feIFN-ωa and feIFN-ωb in detail using bioinformatics followed by soluble expression and optimization of induction conditions in E. coli. Our data showed that purified recombinant feIFN-ωa and feIFN-ωb had broad-spectrum antiviral activity in homologous and heterologous animal cells, suggesting they are candidates for the development of effective therapeutic agents to be used against viral infections in pet cats. And, our research is underway to systematically evaluate the effectiveness of the two novel feIFNs as therapeutics agent for cat viral infections in vivo. In addition, the reported feIFN-ω sequences will enrich the IFN data submitted to GenBank.
Search related documents:
Co phrase search for related documents- amino acid and antiviral activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65
- amino acid and broad spectrum: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- amino acid and characterize identify: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- amino acid and effective therapeutic agent: 1
- amino acid and feIFN ωa: 1, 2, 3
- amino acid and feIFN ωb: 1, 2, 3
- amino acid and feIFN ωb feIFN ωa: 1, 2, 3
- amino acid and ω sequence: 1, 2, 3, 4, 5
- amino acid and induction condition: 1
- amino acid and maximum amino acid homology: 1, 2
- amino acid and maximum nucleotide sequence homology: 1
- amino acid and new subtype: 1, 2, 3, 4
- amino acid and novel effectiveness: 1
- amino acid and nucleotide sequence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77
- amino acid and nucleotide sequence homology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- amino acid and soluble expression: 1, 2, 3, 4, 5
- amino acid and therapeutic agent: 1, 2, 3, 4, 5, 6, 7, 8, 9
- amino acid and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- amino acid homology and feIFN ωa: 1
Co phrase search for related documents, hyperlinks ordered by date